Overview

Each year, tens of millions of people are respectively. The following data indicate diagnosed worldwide with cancer, and the burden (seriousness) of gastrointestinal more than half of these patients eventu- cancer, liver cancer, and colorectal cancers ally die from this disease. The severity of globally and in the United States. (Table 1) the burden of cancer becomes really clear Surgical and molecular therapies and pr- by knowing that there were ? 10, 862, 496 nostic markers for gastrointestinal stromal new cancer cases (excluding skin cancer) tumors are discussed in this volume. Role in the world in 2002, and the number of of anticancer drugs and monoclonal an- deaths caused by this disease in the same bodies specific for these tumors are also year was ? 6,723,887 (GLOBOCAN). discussed. Imaging modality assessing the The number of deaths due to cancer in the effect of anticancer imatinib on these tumors United States was estimated to be 559, 650 is included. Diagnostic and prognostic (Am. Cancer Soc. ). Cancer is caused by markers of clinical outcomes using che- both external factors (tobacco, chemicals, therapy and hormone replacement therapy radiation, and infectious organisms) and for gastric adenocarcinoma are detailed. internal factors (inherited mutations, hor- Also, are discussed immunohistochem- mones, immune conditions, and mutations try of esophageal cancer progression, and that occur from metabolism). diagnostic and therapeutic methodologies All cancer types caused by cigarette for biliary tumors.

Full Product Details

Author:   M. A. Hayat
Publisher:   Springer
Imprint:   Springer
Edition:   Softcover reprint of hardcover 1st ed. 2009
Volume:   3
Dimensions:   Width: 15.50cm , Height: 1.40cm , Length: 23.50cm
Weight:   0.695kg
ISBN:  

9789048180219

ISBN 10:   904818021
Pages:   247
Publication Date:   16 November 2010
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Out of stock  
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

PART I: GASTROINTESTINAL CANCERS 1. INTRODUCTION : GASTROINTESTINAL CANCERS M.A. Hayat GASTROINTESTINAL STROMAL TUMORS (GISTs) GASTRIC CANCER ESOPHAGEAL CANCER TREATMENTS REFERENCES 2. METASTATIC GASTROINTESTINAL CANCER: SAFETY OF CISPLATIN COMBINED WITH CONTINUOUS 5- FLUOROURACIL VERSUS BOLUS 5- FLUOROURACIL AND LEUCOVORIN (METHODOLOGY) Jacqueline Duffour, Oliver Bouche, Philippe Rougier, Chantal Milan, Laurent Bedenne, Jean-Francois Seitz, Bruno Buecher, Jean-Lois Legoux, Michel Ducreux, Denis Vetter, Jean-Luc Raoul, Eric Francois, and Marc Ychou INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION REFERENCES 3. GASTROINTESTINAL CANCER: ENDOSCOPIC SUBMUCOSAL DISSECTION (METHODOLOGY) Atsushi Imagawa INTRODUCTION INDICATIONS METHOD AND DISCUSSION Setting of a High-Frequency Generator Complications Esophageal and Colorectal Lesions REFERENCES 4. GASTROINTESTINAL EPITHELIAL NEOPLASMS: ENDOSCOPIC SUBMUCOSAL DISSECTION (METHODOLOGY) Mitsuhiro Fujishiro INTRODUCTION APPLICATION ENDOSCOPIC SYSTEMS AND EQUIPMENT PROCEDURE Marking Around the Lesion Submucosal Injection Bleeding Perforation Management After Endoscopic Submucosal Dissection FURTHER CONSIDERATIONS REFERENCES 5. INOPERABLE ABDOMINO-PELVIC TUMORS: TREATMENT WITH RADIOFREQUENCY ABLATION AND SURGICAL DEBULKING Nathan W. Pearlman INTRODUCTION TECHNIQUE PATIENT POPULATION AND RESULTS REFERENCES 6. GASTROINTESTINAL NEUROENDOCRINE TUMORS: DIAGNOSIS USING GASTRIN RECEPTOR SCINTIGRAPHY Martin Gotthardt, Thomas M. Behr, and Martin Béhé NEUROENDOCRINE TUMORS Symptoms, Clinical Appearance, Therapy, and Prognosis Diagnostic Imaging Procedures Potential Improvement of Scintigraphic Imaging of NET by Using Alternative Radiopeptides RADIOPEPTIDE SCANNING VERSUS ANATOMICAL IMAGING MODALITIES RADIOLABELED PEPTIDES: DEVELOPMENT, ADVANTAGES AND SHORTCOMINGS MINIGASTRIN FOR DETECTING METASTASIZED NEUROENDOCRINE TUMORS Cholecystokinine 2 (CCK2) Receptor Expression Labeling Scanning Protocol Biodistribution of MG Clinical Imaging in Neuroendocrine Tumors FUTURE PERSPECTIVES OF DGlu1-MINIGASTRIN REFERENCES PART II: ESOPHAGEAL CANCER 7. DISTAL ESOPHAGUS: EVALUATION OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY FUSION IMAGING Domenico Rubello and Cristina Nanni INTRODUCTION 18F-FDG-PET AND PET/CT IN ESOPHAGEAL CANCER Positivity Criteria Staging Disease Relapse NEOADJUVANT THERAPY RESPONSE 18F-FDG-PET/CT VERSUS OTHER TECHNIQUES PET/CT AND OTHER RADIOTRACERS REFERENCES 8. ENDOSCOPIC ULTRASOUND AND STAGING OF ESOPHAGEAL CANCER Kanwar R.S. Gill and Timothy Woodward OBJECTIVES BASIC PRINCIPLES EQUIPMENT PROCEDURE AND TNM CLASSIFICATION ROLE OF ENDOSCOPIC ULTRASOUND-FINE NEEDLE ASPIRATION IN ESOPHAGEAL CANCER ENDOSCOPIC ULTRASOUND IN ASSESSING PRIMARY TUMOR (T STAGING) ENDOSCOPIC ULTRASOUND IN ASSESSING NODAL METASTASIS ENDOSCOPIC ULTRASOUND IN ASSESSING DISTANCE METASTASIS RESTAGING OF ESOPHAGEAL CANCER AFTER CHEMORADIATION ENDOSCOPIC ULTRASOUND-FINE-NEEDLE ASPIRATION MOLECULAR DIAGNOSIS OF ESOPHAGEAL CANCER COMPLICATIONS AND SAFETY REFERENCES 9. ESOPHAGEAL CANCER: ROLE OF RNASEN PROTEIN AND MICRO-RNA IN PROGNOSIS Hideyuki Ishiguro, Yoshiyuki Kuwabara, Nobuyoshi Sugito, and Yoshitaka Fujii INTRODUCTION REAL-TIME REVERSE TRANSCRIPTION ANALYSIS USING TaqMan PROBES Isolation of RNA from Tumor Samples and Reverse Transcription Reaction Real-Time Polymerase Chain Reaction Using TaqMan Probes IMMUNOHISTOCHEMISTRY OF RNASEN REFERENCES 10. ESOPHAGEAL CANCER: INITIAL STAGING Lana Y. Schumacher, Nicole B. Baril, and Sherry M. Wren

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions